Ocean BiomedicalOCEA
OCEA
About: Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
Employees: 7
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
188% more call options, than puts
Call options by funds: $118K | Put options by funds: $41K
1.13% less ownership
Funds ownership: 11.47% [Q2] → 10.34% (-1.13%) [Q3]
28% less capital invested
Capital invested by funds: $4.79M [Q2] → $3.46M (-$1.33M) [Q3]
43% less funds holding
Funds holding: 35 [Q2] → 20 (-15) [Q3]
79% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 19
91% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 11
Research analyst outlook
We haven’t received any recent analyst ratings for OCEA.
Financial journalist opinion
Neutral
GlobeNewsWire
4 weeks ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
PROVIDENCE, Rhode Island, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 18, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”).
Neutral
GlobeNewsWire
1 month ago
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
PROVIDENCE, Rhode Island, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that on April 18, 2024, May 22, 2024, and August 19, 2024, Staff notified the Company that it did not comply with Nasdaq's filing requirements set forth in Listing Rule 5250(c)(1) (the “Rule”) because it had not filed its Form 10-K for the year ended December 31, 2024 (the “Form 10-K”), and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024 (the “Forms 10-Q”), respectively. Based on its review and the materials submitted on June 17, 2024 and August 27, 2024, Staff granted the Company an exception until October 14, 2024, to regain compliance with the Rule. Upon further review, Staff determined that the Company did not meet the terms of the exception. Specifically, the Company has not filed the either its Form 10-K or Forms 10-Q as required by the Rule. The Company will appeal Staff's determination to a Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.
Neutral
GlobeNewsWire
2 months ago
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further the continuation of the program and the development of new YKL-40 inhibitors.
Neutral
GlobeNewsWire
2 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
Ocean Biomedical's Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung Cancer, Glioblastoma, Prostate Cancer, Melanoma, and Breast Cancer
Neutral
GlobeNewsWire
3 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms
Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA ) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking malaria therapeutic antibody discovery that targets PfGARP. Since publicizing news of his original research on PfGARP and its critical role in the malaria cycle in the Journal NATURE , Dr. Kurtis and his team have been working to deepen their understanding of how it naturally triggers the death of malaria parasites, and their control of that mechanism. Their expanded insights have already led to: 1.) a powerful vaccine candidate targeted for long term prevention of malaria infection; 2.) a therapeutic antibody candidate for short term malaria prevention; and 3.) a therapeutic small molecule drug candidate targeted to treat severe malaria, with potential to launch a whole new class of malaria medicines.
Neutral
GlobeNewsWire
3 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
PROVIDENCE, Rhode Island, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”).
Positive
24/7 Wall Street
3 months ago
3 Trending Biotech Penny Stocks
Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons.
Neutral
GlobeNewsWire
6 months ago
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure (VRON-0200), at the EASL 2024 Congress (The European Association for the Study of the Liver), taking place in Milan, Italy from June 5 - 8.
Neutral
GlobeNewsWire
6 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
PROVIDENCE, Rhode Island, May 30, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on May 22, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”).
Neutral
GlobeNewsWire
7 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
Providence, RI, May 16, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA ) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted to both prevent malaria infection and treat severe malaria. Kurtis' novel approach can cause parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This expands patent protection for Dr. Kurtis' novel discoveries at a time when the most common strains of malaria are showing signs of growing resistance to current Artemisinin-based drugs.
Charts implemented using Lightweight Charts™